Nicotinamide Riboside Raises Blood NAD+ 2.3x More than NMN at Equal Dose, Plus Crosses to Brain by Week 4
WELLNESS

Nicotinamide Riboside Raises Blood NAD+ 2.3x More than NMN at Equal Dose, Plus Crosses to Brain by Week 4

By Linda · · Berven et al. 2026 (Acta Medica Cases)
KO | EN

Six healthy middle-aged adults (3 men, 3 women) given 1,200 mg/day of nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) for 8 days in a crossover design showed a 2.3x larger increase in blood NAD+ on NR compared with NMN, according to Berven et al. (February 2026). A follow-up 4-week arm found that NR also elevated brain NAD+ in healthy individuals, but not in Parkinson’s disease patients. This is the first direct clinical comparison positioning NR over NMN among NAD+ precursors.

The study ran in two stages. Stage 1: 6 healthy middle-aged adults received NR 1,200 mg and NMN 1,200 mg for 8 days each in crossover. Result: NR raised blood NAD+ 2.3x more than NMN. Stage 2: 6 healthy adults plus 6 Parkinson’s patients (3 men, 3 women each) received NR or NMN for 4 weeks. Result: at 8 days neither raised brain NAD+; at 4 weeks NR alone raised brain NAD+ in healthy individuals but not in Parkinson’s patients.

NAD+ — The Cellular Energy Currency

Why NAD+ matters:

  • Essential for mitochondrial energy production in every cell
  • Coenzyme for DNA repair (PARP enzymes)
  • Cofactor for sirtuins (SIRT1-7) that regulate aging programs
  • Modulates immune and inflammatory pathways
  • Involved in calcium signaling and stem cell activity

Declines with age:

  • 60s show ~50% of 20s NAD+
  • 80s estimated at 70-80% reduction
  • Hypothesized as a common driver of aging and chronic disease
  • Can supplementation restore it — that’s the open question

Direct NAD+ supplementation does not work:

  • Molecule too large to enter cells
  • Degraded in the GI tract
  • Supplementation uses precursors that the body converts to NAD+

NR vs NMN — What’s the Difference

NMN (nicotinamide mononucleotide):

  • Immediate precursor to NAD+
  • Popularized by Harvard’s David Sinclair
  • Massive market in Japan and China (hundreds of millions in annual sales)
  • Most clinical work in animals or Asian human cohorts

NR (nicotinamide riboside):

  • One step before NMN (NR → NMN → NAD+)
  • Discovered by Charles Brenner, commercialized by ChromaDex
  • FDA NDIN (New Dietary Ingredient Notification) cleared
  • More accumulated safety and clinical data

The standing debate:

  • NMN advocates: “Closer to NAD+ by one step”
  • NR advocates: “NMN isn’t well taken up by cells from blood; NR has superior cell entry”
  • Endless back-and-forth across forums and social platforms
  • No direct comparison until this study

What the Berven 2026 Data Says

Stage 1: 2.3x difference in blood NAD+:

  • Same 1,200 mg dose
  • Same 8-day duration
  • Same 6 subjects in crossover (controls individual variance)
  • NR raised blood NAD+ 2.3x more
  • Statistically and clinically meaningful

Stage 2: brain NAD+ reach:

  • 8 days insufficient for either to raise brain NAD+
  • At 4 weeks NR alone raised brain NAD+
  • Measurement presumably by MRS (magnetic resonance spectroscopy)
  • Suggests superior blood-brain barrier transit for NR

No effect in Parkinson’s:

  • Same 4-week NR supplementation
  • Healthy adults: brain NAD+ rose
  • Parkinson’s patients: no change
  • NAD+ metabolism appears altered in disease state
  • Implications for neuroprotection require further study

Market Implications — Re-alignment of NAD+ Precursor Market

Current market:

  • NMN: ~$500 million global revenue (2025)
  • NR: Tru Niagen and Niagen+ dominate the US and EU
  • Korea, Japan, China lean NMN
  • Pricing: NR ~$30-50/month, NMN ~$50-100/month

Expected shifts:

  • NR advantage on both efficacy and price boosts market share
  • NMN camp counterargument: “8 days is too short, need 4-12 week data”
  • Larger RCTs likely to accelerate
  • NR entry into Asian markets will expand

Rational consumer choice:

  • Efficacy: NR (now data-backed)
  • Price: NR
  • Safety: both good, minimal side effects
  • Awareness: NMN higher in Asia
  • Conclusion on the merits: NR

Women’s Anti-Aging Application

Why this matters for women:

  • Menopause-related NAD+ collapse, synergistic with estrogen decline
  • Mitochondrial aging → muscle loss, fatigue
  • Skin collagen synthesis is NAD+ dependent
  • Cognition and mood effects (SIRT1-mediated)

Practical scenarios:

  • Peri- and post-menopause, ages 40-55
  • Chronic fatigue complaints
  • Slow exercise recovery
  • Subjective cognitive decline
  • Accelerated skin aging

Data-informed dosing:

  • Start with NR 300-500 mg/day
  • Titrate up to 1,000-1,500 mg/day
  • Food timing not critical
  • Pair with B-complex
  • Avoid in pregnancy or lactation (data lacking)

Limitations and Critique

Study limitations:

  • n=6, a very small sample
  • 8 days short, 4 weeks medium — no 12-week or 6-month data
  • Venous, not arterial, NAD+ sampling
  • No clinical outcomes (fitness, cognition, aging markers), only NAD+ levels

Bigger questions:

  • Blood NAD+ is not the same as intracellular NAD+
  • Does brain NAD+ rise translate to cognitive benefit?
  • Effects on aging clocks?
  • What about 12-week or 1-year endpoints?

Commercial caveats:

  • Check Berven team affiliations with ChromaDex (NR manufacturer)
  • Journal ACMCR has a modest impact factor
  • NMN-aligned counter-RCT may follow
  • Don’t decide on a single study

The Bigger Picture — First Real Data Contest in NAD+ Supplementation

Past 5 years:

  • NMN marketing dominated (Sinclair effect)
  • NR accumulated more data but had weaker mindshare
  • Asia split toward NMN, US and EU toward NR

Next 12 months:

  • More head-to-head RCTs at 12 and 24 weeks
  • Pairing with aging clocks (epigenetic, etc.)
  • Single supplement vs. NR + supporting nutrients
  • NR imports into Korean market will grow
  • Price competition will intensify

Women’s lifestyle integration:

  • Peri-menopause bundles (NR + vitamin D + magnesium)
  • Skin aging care combinations (collagen + NR)
  • Exercise recovery support
  • Cognitive support

Bottom Line

NR and NMN — two giants that hadn’t been directly compared — finally went head-to-head, and at equal dose NR won 2.3x. Small sample and short timeline, but the first signal that should shift the market. For women aged 40-55 considering NAD+ supplementation, this is the first guideline-shaped piece of evidence. Single study, though — wait for 12-week and 6-month replications before committing.